Title of Invention

CERAMIC WOUND TREATMENT DEVICE

Abstract A wound treatment device comprising a plurality of separate porous ceramic particles having a porosity of between 25% and 85%, the pores of the particles being interconnected by blow-holes.
Full Text FORM 2
THE PATENTS ACT, 1970 [39 OF 1970]
COMPLETE SPECIFICATION [SEE SECTION 10]
1 TITLE
CERAMIC WOUND TREATMENT DEVICE
APPLICANT

NAME ADDRESS

D & E CRYO CC [ZA/ZA];
22 Siyayi Avenue, 3867 Mtunzini (ZA).

NATIONALITY REPUBLIC OF SOUTH AFRICA
The following specification particularly describes the nature of the invention and the manner in which it is to be performed:-





WO 100/69480 1 PCMB00/O0592
Ceramic Wound Treatment Device
INTRODUCTION AND BACKGROUND TO THE INVENTION
This invention relates to a ceramic wound treatment device and to a method of 5 treating a wound using such device.
United States Patent 3,842,830 discloses a surgical dressing comprising impermeable high silica glass microparticles. The particles are applied directly to the wound. A disadvantage of the surgical dressing is that it is saturated 10 relatively easily, so that a substantial amount of microparticles have to be applied to a wound to have a desirable effect
United States Patent 5,000,746 discloses a covering for wounds comprising a permeable web, which remains flexible during use. The web is made up from a
15 plurality of individually shaped elements connected by connecting members
Into a network, and having, at least on the surface, a layer of ceramic or glass.
.Alternatively, the covering comprises a base, such as a mat, web or fabric,
provided with a glass or ceramic layer. Column 3 lines 14 to 16 of the
specification states that The bodies or elements may be liquid impermeable or
20 they may be porous, and they can suitably be made of a bioinert material, such as aluminium oxide (Al203)." It is therefore dear that the porosity of the elements is not an essential feature of the invention disclosed in that specification and that impermeable glass particles work equally well.


WO 00/69480 PCT/EB00/O0592
2
A disadvantage of a covering of this type is that ft is relatively expensive and difficult to manufacture. Particularly, it is onerous to shape the individual particles and to link the particles together.
5 OBJECT OF THE INVENTION
It is therefore an object of the present invention to provide a ceramic wound treatment device and a method of treating a wound using such device with which the aforesaid disadvantages can be overcome or at least minimised and to provide an effective alternative wound treatment device to conventional 10 wound dressings.
SUMMARY OF THE INVENTION
According to a first aspect of the invention there is provided a wound treatment device comprising a plurality of separate porous ceramic particles. 15
The particles may be contained in a permeable container.
The container may comprise a tea-bag type envelope. Preferably the envelope is of Vilene™.
The ceramic particles may be inert

WO 00/69480

PCT/IBOO/00592

3
The ceramic particles may have a porosity of between 25% and 85%, preferably 75%.
The pores of the particles may have diameters in the range of between 0.3 to 5 30 micrometers.
The pores may be cellular in nature.
The pores may be interconnected by blow-holes. 10
The arrangement may be such that the pores of the ceramic particles apply a capillary suction force to the wound area, thus continuously draining fluid from the area.
15 The particies may be manufactured by pulverising an inert microporous v \ceramic body and removing fine powder from the particles.
The particies may have a diameter range of between 45 and 300 micrometers.
20 According to a second aspect of the invention there is provided a method of treating a wound, the method including the steps of applying to such wound a ceramic wound treatment device as hereinbefore described.

WO 00/69480 PCT/EBOO/00592
4
The invention will now be described further by way of non-limiting examples and with reference to the enclosed drawing which is a cross-sectional end view of a ceramic wound treatment device 10 (CWTD) according to a preferred embodiment of the invention. The CWTD 10 is prepared by a method including 5 the steps of:
milling solid petalite (LiAISi4Oio) into powder (1 micrometer diameter particles);
adding a combustible substance to the powder; mixing the powder with water to form a paste or slurry; 10 - drying out the paste to form a ceramic aggregate;
firing the ceramic aggregate to a temperature of 1200 °C to form an inert microporous solid ceramic body having pore sizes of between 0.3 to 30 micrometers;
pulverising the ceramic body into particles 12 having a diameter of
15 between 45 and 300 micrometers;
removing fine powder and ceramic dust from the particles 12;
disposing the particles in a tea-bag type Vilene™ envelope 14; and sealing the envelope 14.
20 Instead of drying out the paste to form an aggregate, the paste can also be spray-dried to form spherical particles of suitable sizes, which are then sintered at 1200 °C. After the preparation procedure, the ceramic particles are to be kept dry.

WO 00/69480 PCT/IBOO/00592
' 5
The standard wound treatment protocol, irrespective of the type of wound being treated, is as follows:
open the wound by removing any soiled bandages that may previously
5 have been applied to the wound;
optionally applying normal saline (0.9 %) to the wound; optionally cover the wound with a single layer of gauze; apply the CWTD to the wound; and
fasten the CWTD with a bandage, adhesive strip, or transparent cover. 10
EXAMPLE 1 - TREATMENT OF POST-INFECTIVE VENOUS STASIS ULCER
An 84-year old male patient with poor peripheral circulation in both legs, due to
large varicose veins and old age, was subjected to treatment with the CWTD
15 according to the invention. He had developed a large, sloughing ulcer due to
Severe cellulitis of his leg. It had to be surgically debrided and the resulting
ulcer was still very septic and sloughing after-the surgery. The surgeon
anticipated further surgical treatment The patient was not responding to
systematic treatment with quinolone antibiotics and daily povidone iodine
20 dressings. It was feared that the patient would lose either his leg or his life.
The patient was treated according to the above standard wound treatment protocol. Within 48 hours after treatment was started, the wound changed from

WO 00/69480

PCT/IBOO/00592

6
a clearly catabolic state into an anabolic state with granulation tissue forming and slough coming off. The wound started losing its bad odour, despite the fact that it was still pouring out a green coloured pus. Pain from the wound started to diminish and it was clear that the general condition of the patient was also 5 improving.
The CWTD's were applied without wiping or swabbing the wound clean.
The standard protocol was used as follows: 10- the wound was opened by removing the CWTD every morning;
a single layer of dry, woven cotton gauze was applied on the wound;
the CWTD was applied on top of the gauze and secured into place by a
single strip of 10 mm wide adhesive paper tape;
the CWTD was covered with a protective elastic cotton bandage in two
15 layers; and
elastic, compressive stockings were dressed on top of the CWTD every
day as this patient had clinically significant varicose veins.
Results 20 - The CWTD deodorised the wound virtually entirely since the start of treatment. The wound became pain tree after 30 days.

WO 00/69480 PCT/IB00/0O592
' " 7
The rate of healing was above all expectations, especially in the presence of pathogenic bacteria actively forming pus; Despite continuing deterioration in his general condition and recuperative powers, the wound proceeded to heal over 8 months. The wound healed from dimensions of 95mm x 45mm x 18mm to a circular wound of 18mm in diameter and less than 1mm deep when the patient died of combined cardiac and renal failure, unrelated to the wound.
10 EXAMPLE 2 - TREATMENT OF IMPETIGO ULCERS.
A15 year old male with relatively large leg and foot ulcers due to typical lesions of staphylococcal impetigo, was treated with the CWTD according to a modified wound treatment protocol, as set out below. The lesions were about six days old when first seen. They had previously been treated by applying 15 Mercurochrome™ tincture for a few days. It was decided to do a comparative 'treatment by applying a povidone iodine ointment to the ulcer on the shin and the CWTD according to the invention to the ulcer on the toe.
The CWTD's were applied without wiping or swabbing the ulcer on the toe. A 20 modified wound treatment protocol was used as set out below: the ulcer was opened by removing existing dressings; a single layer of dry, woven cotton gauze was applied on the ulcer;

WO 00/69480 PCT/IBOO/00592
' '" 8
the CWTD was applied on top and secured into place by a single strip of 10 mm wide adhesive paper tape;
the CWTD was then covered with a protective elastic cotton bandage in two layers; 5 - The CWTD was the only mode of topical treatment on the toe.
Results
Both ulcers were healing well at the first follow up on day 6, but only the toe ulcer had healed by day 26. The leg ulcer was still being treated by topical
10 iodine and was not showing signs of healing. The patient requested on day 26 to have the CWTD applied to the shin ulcer as well. On day 26 (after being without the CWTD for 5 days) the patient returned with a very septic shin lesion. Interestingly enough the defect had partially closed despite the new sepsis. An initial 5 day course of oral treatment, comprising 2 cortrimoxazole
15 tablets twice a day and Asprin (600 mg) was administered. After day 5, only topical treatment was applied. The patient defaulted twice on treatment and was without CWTD for 3 days the first time and for 5 days the second time. The shin wound healed uneventfully within 26 days from the start of the treatment.
20 EXAMPLE 3 - TREATMENT OF RECURRENT VENOUS STASIS ULCER.
A 72 year old female patient with pour peripheral circulation in both legs due to varicose veins, obesity and age, was subjected to treatment. She had an ulcer

WO 00/69480 PCT/IB00/00592
9
in the same position a year before. Minor trauma started the present ulcer 6 weeks prior to this first visit.
The patient was treated according to the standard wound treatment protocol as 5 follows:
the wound was opened by removing dressings;
a single layer of dry, woven cotton gauze was applied to the wound;
the CWTD was applied on top and secured into place by a single layer
of 10 mm wide adhesive paper tape. The CWTD's were applied without
10 wiping or swabbing the wound clean;
the CWTD's were covered with a protective elastic cotton bandage in
two layers;
during the last three weeks of treatment, the CWTD's were left in place
for 5 days at a time.
15 No antibiotics were administered either topically or systemically.
The patient could not afford an elastic compressive stocking as would
have been indicated for use in her case.
The patient lived in a hut made of sticks and mud with very rudimentary
ablution facilities. 20
Results
The CWTD deodorised the wound almost completely.

WO 00/69480 PCT/IB00/00S92
10
The rate of healing was above all expectations, especially in the presence of old scar tissue.
The wound was completely healed with good quality scar tissue by day
58. On follow up after one year, the scar had remained stable with
5 surprisingly good aesthetic appearance.
EXAMPLE 4 - TREATMENT OF SEPTIC POST-OPERATIVE WOUND
A 34 year old female patient who had delivered her second child by Caesarean section three weeks before, were treated with the CWTD. A puncture wound on 10 the side of the Pfannenstiel incision did not heal and was continually oozing serous fluid. The patient had been treated with povidone iodine dressings after first cleaning the wound with Eusol™
The wound was treated according to the standard protocol. The patient treated 15 the wound at home and continued to do her home work as usual.
v
initially the wound healed well, but after about 9 days a second wound, adjacent to the first lesion opened up on the scar. The skin now appeared to have developed an allergy to the Micropore™ adhesive tape. It was decided to 20 stop ail treatment for 48 hours and then to resume without the adhesive tape. A moderate strength topical cortisone cream was applied to the irritated skin during these two days. Upon resumption of treatment with the CWTD, the skin immediately became irritated again, when the patient realised that it was the

WO 00/69480 PCT/EB00/00592
11
hypochioride solution that was causing the irritation, and thereafter used normal saline for wetting the wounds.
Results
5 Both wounds then proceeded to heal uneventfully and both wounds were healed by day 34.
EXAMPLE 5 - TREATMENT OF VENOMOUS BITE WOUND
A 39 year old female patient with a venomous bite (possibly a spider) on the 10 sole of her foot was treated with the CWTD. The patient was first seen on day 6 after the injury. The lesion had a small area of central necrosis about 5mm in diameter and 3 mm deep with an area of hyperaemia, about 25 mm by 35 mm, where the skin looked injured.
15 Treatment with the CWTD commenced on day 6, according to the standard \ treatment protocol. No other treatment was used.
Results
The patient returned for follow up on day 10 of treatment. The lesion showed 20 the following features:
the dead skin had come off to its full extent;
the base was completely clean and covered by healthy granulation
tissue; and

WO 00/69480 PCT/IBOO/00592
12
re-epithelialisation was in rapid progress.
The patient returned finally on day 24 of treatment with the lesion completely closed and no further treatment was required. The patient continued to work 5 throughout her treatment and had only mild discomfort form the slightly bulky CWTD on the bottom of her foot
EXAMPLE 6
A 25 year old male patient who was involved in a car accident was furthermore 10 treated with the CWTD. He had sustained an injury to his left buttock area
extending from the edge of the gluteal fold into the external sphincter of the
anus. A laceration extended 5 cm laterally from the lower edge of the injury.
The sphincter defect was repaired surgically in a nearby hospital. The repair
was successful. The patient declined to have a colostomy done to cut off the
15 faecal stream from passing over the injured area. He rather opted to see if the
', wound would heal without such drastic measures. The patient had no medical
insurance and asked to be discharged on day 3 after the repair. The patient
began treatment with CWTD on day 8 of the injury.
20 The CWTD was applied twice per day, after a 5-minute sitz bath in diluted Savion™.

WO 40/69480 PCT/IB00/00592
13
Results
By the 5th day of use of the CWTD, the wound showed good granulation and de-sloughing. The patient was out of bed by this time and his pain was well controlled by no more than moderate strength oral analgesics once or twice per 5 day. His wound was now easily treated at home. On day 18 of treatment with the CWTD, the wound started showing rapid healing, good quality granulation tissue and a steadily advancing edge of good quality skin covering the defect.
The patient went back to work on day 20 of treatment and continued to apply 10 the CWTD twice per day following the standard treatment protocol. The wound of the patient was completely healed after 42 days of treatment The wound remained stable after one year with minimum scarring after 6 months. The patient is fully continent after treatment.
15 CONCLUSION
\The following observations are common with patients treated with the CWTD's according to the invention:
The wound area heals visibly despite the presence of adverse elements such as pathogenic bacteria and dead tissue (slough); 20 - Excess fluids and bad odours are removed;
The patients generally experience less pain or cessation of pain altogether from their wounds;

•WO 00/69480 PCMB0O/O0S92
14
The treatment produces similar results irrespective of the cause of the
wound;
The CWTD's work well in the absence of aseptic application techniques.
The mode of application is simple and easy to understand and the
5 wounds can therefore be treated by the patients themselves or by lay
care givers in the home environment or in an active work environment.
The CWTD's are able to allow wounds to heal irrespective of the cause
or location of the wound, the presence of superficial pathogenic infective
agents, the age of the wound or previously applied treatments. 10 - Furthermore, the healing process can proceed irrespective of the level of
literacy, social class or age of the patient, his/her physical
circumstances, the availability of trained care givers or patient
expectations and, all of this at home.
15 The following types of ulcers and wounds were treated thus fan
septic post infective lower leg ulcers;
ulcers of impetigo;
varicose and venous stasis ulcers of legs;
venomous bite ulcers; 20 - lacerations too old to suture;
septic post- operative wounds;
septic para-unguinal (big toe) lesions;
newly sutured lacerations - (much better cosmetic results seen);

WO 00/69480 PCT/IBOO/00592
15
dog bites;
dehiscence of post operative wound; septic diabetic ulcers; post faschiotomy wound; 5 - tissue loss;
post cryotherapy (liquid nitrogen therapy of skin lesions); burn wounds; and decubitus ulcers.
10 The applicant believes that the large surface area and the accompanying capillary suction forces caused by the pores of the ceramic particles contribute to the effectiveness of the wound treatment device according to the invention in the treatment of wounds and the like. By continuous siphoning of the excess wound exudate, the balianced order of cell signals is restored and wound
15 healing optimised irrespective of the cause of the wound or the stage at which ^the treatment was started.
It will be appreciated that variations in detail are possible with a ceramic wound treatment device, according to the invention, without departing from the scope 20 of the appended claims.

We claim:
1. A wound treatment device comprising a plurality of separate porous ceramic particles having a porosity of between 25% and 85%, the pores of the particles being interconnected by blow-holes.
2. A wound treatment device as claimed in claim 1 wherein the particles are contained in a permeable container.
3. A wound treatment device as claimed in claim 2 wherein the container comprises a tea-bag type envelope.
4. A wound treatment device as claimed in claim 1 wherein the ceramic particles are inert.
5. A wound treatment device as claimed in claim 1 wherein the ceramic particles have a porosity of 75%.
6. A wound treatment device as claimed in claim 1 wherein the pores of the particles have diameters in the range of between 0.3 to 30 micrometers.
7. A wound treatment device as claimed in claim 1 wherein the pores are cellular in nature.
8. A wound treatment device as claimed in claim 1 wherein the particles are manufactured by pulverizing an inert microporous ceramic body and removing fine powder from the particles.
9. A wound treatment device as claimed in claim 1 wherein the particles have a diameter of between 45 and 300 micrometers.
10. A method of treating a wound, the method including the steps of applying to such a
wound a ceramic wound treatment device as claimed in claim 1.
Dated this 9th day of December 2001
D&ECryo CC BY THEIR ADVOCATES-IP
SHYSM SUNDER IYER PATENT AGENT TAS&CO
To,
THE CONTROLLER OF PATENTS
THE PATENT OFFICE, MUMBAI

Documents:

in-pct-2001-01396-mum-cancelled pages-(18-01-2005).pdf

in-pct-2001-01396-mum-claims(granted)-(18-01-2005).doc

in-pct-2001-01396-mum-claims(granted)-(18-01-2005).pdf

in-pct-2001-01396-mum-correspondence(18-01-2005).pdf

in-pct-2001-01396-mum-correspondence(ipo)-(13-03-2007).pdf

in-pct-2001-01396-mum-form 19(7-10-2003).pdf

in-pct-2001-01396-mum-form 1a(19-05-2004).pdf

in-pct-2001-01396-mum-form 2(granted)-(18-01-2005).doc

in-pct-2001-01396-mum-form 2(granted)-(18-01-2005).pdf

in-pct-2001-01396-mum-form 3(18-01-2006).pdf

in-pct-2001-01396-mum-form 3(9-11-2001).pdf

in-pct-2001-01396-mum-form 5(8-11-2001).pdf

in-pct-2001-01396-mum-form-pct-ipea-409(9-11-2001).pdf

in-pct-2001-01396-mum-form-pct-isr-210(9-11-2001).pdf

in-pct-2001-01396-mum-power of authority(11-03-2002).pdf


Patent Number 205065
Indian Patent Application Number IN/PCT/2001/01396/MUM
PG Journal Number 31/2007
Publication Date 03-Aug-2007
Grant Date 13-Mar-2007
Date of Filing 09-Nov-2001
Name of Patentee D & E CRYO CC
Applicant Address 22 SIYAYI AVENUE, MTUNZINI, 3867, REPUBLIC OF SOUTH AFRICA.
Inventors:
# Inventor's Name Inventor's Address
1 EISELEN, ERNST, RICHARD [ZA/ZA] 5 STATION ROAD, 3867 MTUNZINI (ZA)
PCT International Classification Number A61L 15/18
PCT International Application Number PCT/IB00/00592
PCT International Filing date 2000-05-08
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 99 / 3273 1999-05-12 South Africa
2 99/6118 1999-09-23 South Africa